Tag Archives: License Agreement

Business, Finance, Occupation & Industry

Acacia Subsidiary Enters into Settlement and License Agreement with Other World Computing, Inc.

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Acacia Subsidiary Enters into Settlement and License Agreement with Other World Computing, Inc.

NEWPORT BEACH, Calif.–(BUSINESS WIRE)– Acacia Research Corporation (NAS: ACTG) announced today that its Brandywine Communications Technologies LLC subsidiary has entered into a settlement and license agreement with Other World Computing, Inc. This agreement resolves litigation that was pending in the United States District Court for the Northern District of Illinois.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation‘s subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research Corporation‘s subsidiaries control over 250 patent portfolios, covering technologies used in a wide variety of industries.

Information about Acacia Research Corporation and its subsidiaries is available at www.acaciaresearchgroup.com and www.acaciaresearch.com.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Acacia Research Corporation
Rob Stewart, Investor Relations
Tel 949-480-8300
Fax 949-480-8301
or
Media Contact:
SpecOps Communications
Adam Handelsman, President & Founder
212-518-7721
adam@specopscomm.com

KEYWORDS:   United States  North

From: http://www.dailyfinance.com/2013/04/18/acacia-subsidiary-enters-into-settlement-and-licen/

Business, Finance, Occupation & Industry

Furiex Pharmaceuticals to Receive Milestone Payment for Priligy® Launch in France

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Furiex Pharmaceuticals to Receive Milestone Payment for Priligy® Launch in France

MORRISVILLE, N.C.–(BUSINESS WIRE)– Furiex Pharmaceuticals, Inc. (NAS: FURX) , a drug development collaboration company, today announced it will receive a $5.0 million milestone payment from the Menarini Group for the launch of Priligy in France. Currently, Priligy is marketed for on-demand treatment of premature ejaculation in 16 countries in Europe, Asia and Latin America, and is approved for that indication in 56 countries worldwide.

In May 2012, Furiex entered into a license agreement with Menarini to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Under the terms of the License Agreement, Furiex is eligible to receive an additional $5.0 million launch milestone and up to $40.0 million in sales-based milestones, plus tiered royalties ranging from the mid-teens to mid-twenties in percentage terms.

“This launch will make Priligy, the only approved medication for premature ejaculation, available to a wider market in the EU,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “We look forward to additional worldwide Priligy launches as Menarini continues to build this franchise.”

About Premature Ejaculation

Premature ejaculation (PE) is a distressing sexual dysfunction that can be present from the first sexual encounter or can develop later in life. It is the most common male sexual dysfunction, affecting about 30 percent of the male adult population at some point during their lives. The condition consists of three major components: a short time to ejaculation, lack of ejaculatory control and negative personal impact, including distress related to rapid ejaculation. A combination of physiological and psychological factors is believed to influence the mechanism of ejaculation. Research suggests serotonin plays a central role in the timing of ejaculation.

About Priligy

Priligy (dapoxetine) is the first oral medication approved for “on-demand” treatment of PE. It is a unique, short-acting, selective serotonin reuptake inhibitor designed to be taken only when needed – one to three hours before sexual intercourse is anticipated – rather than every day. Priligy was evaluated in five randomized, placebo-controlled Phase III clinical trials involving more than 6,000 men with PE and their partners. This is the largest and most comprehensive clinical trial program to date for a drug therapy to treat PE. Priligy is approved for on-demand treatment of PE in 56 …read more

Source: FULL ARTICLE at DailyFinance